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Acute bronchiolitis, which is the most common acute lower respiratory system 
disease, is resulting in significant morbidity and mortality in children less than 
2 years. Respiratory syncytial virus (RSV) is the most common causative pathogen 
for over 30 million new acute lower respiratory infection episodes in children under 
5 years of age. Rhinovirus, adenovirus, influenza virus, parainfluenza, and other 
respiratory viruses also cause acute bronchiolitis as the sole pathogen or as coinfec-
tion with or without RSV. Cardiovascular disease, chronic pulmonary disease, 
immunodeficiency, and premature birth are important risk factors for hospital-
ization and increase the risk of acute bronchiolitis-associated respiratory failure 
or even death. Bronchiolitis is a clinical diagnosis that varies from mild illness to 
severe respiratory failure. The severity of bronchiolitis is evaluated with several 
parameters including wheezing, retraction, respiratory rate, and general situation. 
However, the most important clinical finding is the presence or absence of hypox-
emia and whether the patient can tolerate respiratory distress. Fluid support and 
oxygen supplementation by nasal cannula, face mask, or head box are critical for 
the treatment of bronchiolitis. Commonly used bronchodilators, corticosteroids, 
ribavirin, and antibiotics have not been shown to be effective in improving the 
clinical course of the bronchiolitis.
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1. Introduction
Acute bronchiolitis is the most common lower lung disease that causes substan-
tial morbidity and hospitalization in young infants under 6 months of age [1, 2]. 
In the first year of life, approximately 20–30% of children suffer from acute bron-
chiolitis that is frequently seen during the winter season, and infants are hospital-
ized with bronchiolitis [3]. During the epidemic season (late-autumn and winter 
months), the rate of bronchiolitis requiring hospitalization in all infants smaller 
than 12 months have been reported as 3% of in the US and Europe [4]. Prematurity 
and being born during the RSV season are risks factors for hospitalization [5]. A 
recent study has stated that the rate of hospitalization for bronchiolitis is 5.4% in 
preterm infants in the first 12 months of life [6]. A few studies particularly focused 
on the costs of bronchiolitis hospitalization reported that bronchiolitis admissions 
cost more than 500 million dollars annually and a co-diagnosis of bronchiolitis and 
pneumonia almost doubles the cost of the hospitalization [7].
Bronchiolitis is a viral disease in the infant period. Respiratory syncytial virus 
(RSV) is the most common agent that causes 50–80% of the cases. Its peak clinical 
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severity is seen between third and fifth days. Respiratory syncytial virus bron-
chiolitis is responsible for a short history of low-grade fever, cough, coryza, and 
difficulty in breathing and feeding. Infants who are under 6 weeks of age might be 
present with apnea alone without other clinical symptoms [8]. There are several 
predispositions to developing RSV infection in infants. A few of them are presence 
of an older sibling, birth in the RSV season, low birth weight, male sex, young 
age (<6 months), exposure to smoking, young maternal age, and suburban resi-
dence. Having congenital heart disease, chronic lung disease, immunodeficiency, 
cystic fibrosis, Down syndrome, or cerebral palsy increases the severity of RSV 
bronchiolitis [9]. In the pathogenesis of RSV bronchiolitis, there are a defective 
inflammatory response and cellular damage related to viral replication. Annually, 
RSV associated with lower respiratory tract infection in infants and young children 
leads to around 3.2 million hospitalizations and 59,000 deaths worldwide [10]. 
To date, there is no modality to prevent RSV infection. RSV vaccines, that named 
a formalin-inactivated RSV vaccine, have been improved in the mid-1960s. Due 
to the fact that the vaccines had caused “vaccine enhanced disease”, the subunit 
vaccines schedule were not recommended. Afterward, RSV immune globulin 
(RespiGamTM) that reduced RSV-mediated hospitalizations had been prophylac-
tically developed for infants with several risks for severe RSV disease. Currently, 
SynagisTM (palivizumab) is used to decrease RSV related hospitalizations by 
>55%. SynagisTM is implemented for newborns with a birth age of 35 weeks or 
less and infants under 6 months in RSV season. Additionally, for under 2 years, 
children with chronic lung disease treatment and hemodynamically serious 
congenital heart disease in the last 6 months are proposed to prevent severe RSV 
infection with the monoclonal antibody. SynagisTM should be given once a month 
at a dose of 15 mg/kg as long as the risk of RSV infection persists [11]. No mat-
ter what virus, the main treatment of bronchiolitis is liquid and oxygen therapy. 
However, Alansari et al. tested the efficacy of the anti-RSV monoclonal antibody 
palivizumab in infants <3 months of age with RSV bronchiolitis. Results of clini-
cal trials have shown that intravenous palivizumab did not appear to help young 
infants with acute RSV-positive bronchiolitis [12]. Not only RSV has been reported 
as the most common cause of acute bronchiolitis in children younger than 1 year, 
but also the global annual rate of RSV hospitalization among children <5 years is 
4.4 per 1000 lower respiratory tract infection in a systematic review and meta-
analysis [8, 9, 13, 14]. History of prematurity is also reported to be a leading cause 
of mortality in acute bronchiolitis [15]. Due to the fact that the RSV vaccine is not 
available, prophylaxis with the monoclonal antibodies, palivizumab and motavi-
zumab, has been developed to prevent RSV associated with mortality-morbidity in 
premature infants [16].
Rhinovirus is the second most common pathogen in acute bronchiolitis. 
Epidemiologic studies have stated that rhinoviruses-A and -C are to be the more 
common subtype acute respiratory infections and wheezing illnesses, and have 
reported that rhinovirus is related to moderate and severe bronchiolitis and in 
childhood [17]. In COAST cohort study, rhinovirus-A and -C species were associ-
ated with a higher risk of moderate-to-severe acute respiratory infection compared 
with those with rhinovirus-B infection [18]. The prevalence of rhinovirus causing 
acute lower respiratory infection varies between 17 and 35% among young children. 
A study from Turkey conducted by Gökçe et al. showed that the respiratory viral 
agent exhibited seasonal patterns with the number of RSV and rhinovirus cases 
peaking in the winter season [19]. Data on long-term outcomes report that the rate 
of recurrent wheezing is significantly higher in rhinovirus infections. Additionally, 
several cohorts confirmed that rhinovirus causing wheezing illness in early life is 
a significant predictor of asthma. Teeratakulpisarn et al. showed that the children 
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diagnosed with rhinovirus bronchiolitis could be possessed of recurrent wheez-
ing. However, these symptoms mostly disappeared before the age of 6, and nearly 
half of the study patients subsequently had asthma [20, 21]. Another study from 
Italy also showed that recurrent wheezing 36 months after infant bronchiolitis was 
associated with rhinoviruses and blood eosinophilia [22].
Studies have reported that influenza, coronavirus, adenovirus, human bocavi-
rus, human metapneumovirus, and parainfluenza viruses cause acute bronchiolitis 
as the sole pathogen or as coinfection with a similar seasonal pattern. Miron et al. 
aimed a study to assess the prevalence of sole and mixed respiratory organisms 
infection/detection in young children diagnosed with acute bronchiolitis. In this 
study, 590 respiratory organisms were detected in 423 (91%) children, and the two 
most commonly detected agents were RSV and rhinovirus [23]. In bronchiolitis, the 
most common dual infection was between RSV and rhinovirus, and the second was 
between RSV and human bocavirus. Adenovirus coinfections were also reported as 
the third most frequent. A study conducted in the United States asserted that dual 
infections had more ratios of hospitalizations than single infections [24]. Contrary, 
Calvo et al. stated that coinfections do not increase the severity [25].
The risk of acute bronchiolitis-associated respiratory failure or death is more 
seen in children previously diagnosed with cardiovascular disease, chronic 
pulmonary disease, and immunodeficiency. Persistently increased respiratory 
effort, hypoxemia, apnea, and acute respiratory failure define severe bronchiolitis 
that requires intensive monitoring and repeated examinations. Risks of severe 
bronchiolitis generally increase in infants with chronic lung disease, congenital 
heart disease, anatomic defects of the airways, immunodeficiency, and neurologic 
disease. It has also been reported that male gender, indigenous status, exposure to 
tobacco smoke, and poor socioeconomic factors were to be associated with severe 
bronchiolitis. Various polymerase chain reaction (PCR) techniques provide us to 
diagnose the etiology of acute bronchiolitis.
The clinical studies for new diagnostic measurements have been brought forth 
by clinicians in order to predict severe bronchiolitis, because severe bronchiolitis 
might be associated with morbidity and mortality in infants. It has been found 
that children with RSV had a more severe initial clinical presentation. Bamberger 
et al. stated that infants with RSV bronchiolitis, especially young infants, had high 
clinical severity score on admission when compared to those with other respiratory 
viruses [26]. In this respect, it has been aimed to evaluate the accuracy of virologic 
testing for RSV in detecting patients at risk for more severe disease. Hasegawa et al. 
have reported that the major viruses (RSV-A, RSV-B, rhinovirus, adenovirus, and 
hMPV) had different temporal patterns in a study which was multicenter-multiyear 
prospective cohorts of the US infants with severe bronchiolitis. Their data provide 
guidance for optimal timing of RSV immunoprophylaxis, effective prophylactic 
(e.g., immunoprophylaxis), and treatment (e.g., antiviral agents) strategies in 
infants at higher risk for severe bronchiolitis [27]. Another study stated that infants 
attended daycare, had older siblings, had high parental educational levels, had 
birth weights of >4 kg, and were born between April and September had a 10-fold 
higher risk for severe RSV infection than those who had no these factors [28]. These 
features provide us to differentiate between infants with high risks of RSV bronchi-
olitis and to target preventive and monitoring approach.
2. Pathophysiology and pathogenesis
Generally, acute bronchiolitis is characterized by upper respiratory symptoms 
(e.g., rhinorrhea) followed by lower respiratory infection with inflammation 
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which is commenced by a pathogen and leads to epithelial necrosis in the bronchial 
epithelium. Classical symptoms of bronchiolitis including wheezing, crackles, and 
bronchospasm consist of partial obstruction in the lumen through the accumulation 
of degenerated squamous epithelium secretions [29]. Bronchiolar obstruction with 
edema and accumulation of mucus and cellular debris in the airways can persist 
for many weeks or months following acute bronchiolitis [30]. The reconstruction 
process may result in complete recovery. However, it can also be characterized by 
exaggerated proliferation of granulation tissue. There is an exaggerated inflamma-
tory response mediated by cytokines especially T-helper 1 in the pathogenesis of 
acute bronchiolitis with a variable cytokine profile, according to the infective virus. 
Due to the fact that exaggerated proliferation causes narrowing or obliteration of 
the airway lumen, severe clinical findings can be seen in some cases [31–33].
The mucosal innate immune system procures a strong barrier to respiratory 
infections. In particular, RSV and/or rhinovirus can trigger/induce the concomi-
tant production of type I (IFNα/β) and type III (IFNλs). A study was designed to 
investigate the airway type III IFN receptor (IFNLR1/IL10RB) expression during 
respiratory syncytial virus or human rhinovirus bronchiolitis. The results of this 
study showed that the association of IFNLR1 with rhinovirus infection could cause 
more severe bronchiolitis and blood eosinophilia. The type III IFN receptor also 
dictates an important role in the host immune response during bronchiolitis [34].
2.1 Etiology
Respiratory syncytial virus is the most common etiologic pathogen in acute 
bronchiolitis with a rate of 50–80%. Various studies have shown that other viruses, 
including adenovirus, coronavirus, parainfluenza, influenza, rhinovirus, human 
bocavirus, and human metapneumovirus, are associated with acute bronchiolitis 
[35]. Rhinovirus (RV), which is the most common human respiratory pathogens and 
are responsible for most upper respiratory infections (e.g., the common cold), is the 
second most commonly associated viral bronchiolitis [36–38]. In recent years, new 
human respiratory viruses like human metapneumovirus, human bocavirus, and 
new human coronaviruses have also been reported as possible pathogens causing 
acute bronchiolitis [38]. Respiratory viruses could occur as coinfection with other 
respiratory viruses: dual, triple, or more [37, 39, 40]. Today, various viral diagnostic 
tests provide us to determine the epidemiological differences/clinical characteristics 
of respiratory viruses. One of the diagnostic methods is multiplex polymerase chain 
reaction which has been the most commonly used method [41]. Rarely, several atypi-
cal infections, for instance, Bordetella pertussis, Mycoplasma pneumonia, Simkania 
negevensis, and a Chlamydia-like intracellular organism have also shown in bronchi-
olitis [42–44].
2.2 Diagnosis
American Academy of Pediatrics Clinical Practice Guidelines has reported the 
definition of acute bronchiolitis in 2006. According to the guideline, bronchiolitis 
has been described as the first episode of wheezing in children under 24 months of 
age who have respiratory findings during the viral infection episode. Tachypnea, 
nasal flaring, chest retractions, and wheezing and/or rales are clinical characteristic 
features of acute bronchiolitis. Rhinorrhea, cough, tachypnea, wheezing, rales, and 
increased respiratory effort manifested as grunting, nasal flaring, and intercostal 
and/or subcostal retractions are clinical signs and symptoms of bronchiolitis [3]. 
Early presentations of asthma or wheeze with viral infections may potentially over-
lap with the diagnosis of bronchiolitis. Chest radiographs and laboratory studies 
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may be thought of on clinical suspicion after evaluating the differential diagnosis 
for secondary or comorbid bacterial infection, complications, or other conditions.
Viral diagnosis methods that are not routinely suggested for testing, including 
antigen detection or immunofluorescence of nasal secretion wash or nasal aspira-
tion, rapid antigen tests, and PCR, are only suggested for identifying specific viral 
agents in children with bronchiolitis if the results will determine discontinuation of 
palivizumab prophylaxis, initiation, or continuation/discontinuation of antibiotic 
therapy [45–48].
Bronchiolitis must be distinguished from a variety of acute and chronic diseases 
including asthma, pneumonia, airway lesions, congenital lung disease or diaphrag-
matic hernia, cystic fibrosis, congenital heart disease, sepsis, and severe metabolic 
acidosis that might present with similar presentation. Atypical clinical findings 
like lack of preceding upper respiratory tract symptoms, witnessed an episode of 
choking, and poor growth may be useful to discriminate from acute bronchiolitis. It 
should be considered further investigation for the differential diagnosis.
2.3 Hospital admission and investigations
Though bronchiolitis is usually a self-limiting entity, several infants have 
severe bronchiolitis and should be safely managed at hospital. Severity score of 
bronchiolitis is described with several clinical parameters including wheezing, 
retraction, respiratory rate, and general situation (Wang respiratory score) [49]. 
However, the severity score has not been shown to be useful in a clinical setting. 
Therefore, the scoring system is not generally used in hospitalization decision. If 
the infants have any of features, such as apnea, difficulty in feeding, severe respira-
tory distress with accessory muscle use or grunting, respiratory rate greater than 
60/min, diagnostic uncertainty, and cyanosis/hemoglobin saturation < 92%, they 
are should be referred for hospital admission. Infants with specific risk factors, 
such as poor socioeconomic circumstances, a history of prematurity, congenital 
heart disease, or chronic lung disease, also need to be hospitalized. Around 1–5% of 
infants might need pediatric intensive care support in bronchiolitis [50]. If infants 
under 6 months of age or with comorbidities, they are more likely to require inten-
sive care unit admission. After hospitalization, the infants with severe respiratory 
distress, exhaustion, failure to maintain hemoglobin saturation above 92–94% with 
supplemental oxygen or with recurrent apnea should be followed-up in intensive 
care units. Since the diagnosis of acute bronchiolitis is done clinically, infants 
with bronchiolitis require no further investigations. During the hospitalization, 
hemoglobin saturation should be measured using pulse oximetry to determine the 
requirement for supplemental oxygen.
2.4 Assessment
Initially, the management of bronchiolitis is assessed by clinical features. 
Persistently increased respiratory effort, hypoxemia, apnea, and acute respira-
tory failure show severe bronchiolitis. Therefore, basic airway management and 
emergency endotracheal intubation should be considered in a child with deteriora-
tion and respiratory failure. In nonsevere bronchiolitis, supportive care including 
adequate hydration and relief of nasal congestion/obstruction are the mainstays 
of management for infants with bronchiolitis. Disease progression should also be 
monitored. Although bronchodilators (inhaled or oral), glucocorticoids, nebulized 
hypertonic saline, or leukotriene inhibitors have been used in some situations, 
randomized trials do not recommend pharmacologic interventions in nonsevere 
bronchiolitis.
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Fluid support is absolutely necessary for infants with any level bronchiolitis. 
Because bronchiolitis causes difficulty in maintaining adequate hydration and 
children with bronchiolitis may also decrease intake the fluid due to tachypnea 
and respiratory distress. Related to clinical features, fluid replacement treatment 
may have been provided by parenteral or small frequent feedings or orogastric or 
nasogastric feedings in children who can tolerate enteral feedings strategies.
The second most important support treatment is oxygen supplementation by 
nasal cannula, face mask, or head box to provide the SpO2 > 90–92% for infants. If 
there is insufficient oxygen therapy during support treatment, it means that a pro-
gression to respiratory failure. In order to reduce the work of breathing, improve gas 
exchange, and avoid the need for endotracheal intubation, heated humidified high-
flow nasal cannula (HFNC, also called high-flow warm humidified oxygen) therapy 
and/or continuous positive airway pressure (CPAP) are recently used mostly.
2.5 Clinical course
Bronchiolitis, which is a self-limited disease, often resolves without complica-
tions. Generally, the respiratory status improves over 2–5 days in bronchiolitis. 
Standard strategies include hand hygiene to reduce the risk of bronchiolitis to mini-
mize the transmission of infectious agents. Additionally, avoiding passive exposure 
to cigarette smoke and contact with individuals with respiratory tract infections 
might reduce the risk of bronchiolitis.
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